The association between regular cannabis exposure and alterations of human brain morphology: An updated review of the literature

Current Pharmaceutical Design

Volumn 20, Issue 13, 2014, Pages 2138-2167

  Lorenzetti, Valentina ^a,b   Solowij, Nadia ^c   Fornito, Alex ^a,b   Lubman, Dan Ian ^a   Yücel, Murat ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Amygdala; Brain; Cannabis; Cerebellum; Hippocampus; Prefrontal cortex; sMRI

Indexed keywords

CANNABIS; ILLICIT DRUG; DRONABINOL;

BRAIN REGION; BRAIN SIZE; CANNABIS USE; CEREBELLUM CORTEX; CEREBROSPINAL FLUID; COGNITION; EXPOSURE; FRONTAL CORTEX; GRAY MATTER; HUMAN; MENTAL DISEASE; MORPHOLOGY; NEUROIMAGING; PRIORITY JOURNAL; REVIEW; TEMPORAL CORTEX; ADOLESCENT; ADULT; ANIMAL; BRAIN; DRUG EFFECTS; EMOTION; FEMALE; MALE; PATHOLOGY; TOXICITY;

ADOLESCENT; ADULT; ANIMALS; BRAIN; CANNABIS; COGNITION; DRONABINOL; EMOTIONS; FEMALE; HUMANS; MALE;

EID: 84903737100     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990435     Document Type: Review

References (253)

1. UNODC. World drug report 2010: United Nations Office on Drugs and Crime 2010.
2. Swift W, Hall W, Teesson M. Cannabis use and dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing. Addiction 2001; 96(5): 737-48.
3. Chen CY, O'Brien MS, Anthony JC. Who becomes cannabis dependent soon after onset of use? Epidemiological evidence from the United States: 2000-2001. Drug Alcohol Depend 2005; 79(1): 11-22.
4. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009; 374(9698): 1383-91.
5. Solowij N, Battisti R. The Chronic Effects of Cannabis on Memory in Humans: A Review. Curr Drug Abusers Rev 2008; 1.
6. Solowij N, Stephens R, Roffman RA, Babor T. Does marijuana use cause long-term cognitive deficits? Jama 2002; 287(20): 2653-4; author reply 4.
7. Gaoni Y, Mechoulam R. The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc 1971; 93(1): 217-24.
8. Scallet AC, Uemura E, Andrews A, et al. Morphometric studies of the rat hippocampus following chronic delta-9-tetrahydrocannabinol (THC). Brain Res 1987; 436(1): 193-8.
9. Landfield PW, Caldwallader LB, Vinsant S. Quantitative changes in hippocampal structure following long-term exposure to Δ9-tetrahydrocannabinol: possible mediation by glucocorticoid systems. Brain Res 1988; 443(1-2): 47-62.
10. Heath RG, Fitzjarrell AT, Fontana CJ, Garey RE. Cannabis sativa: Effects on brain function and ultrastructure in rhesus monkeys. Biol Psychiatry 1980; 15(5): 657-90.
11. Lawstone J, Borella A, Robinson JK, Whitaker-Azmitia PM. Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55,212-2. Brain Res 2000; 877: 407-10.
12. Lorenzetti V, Lubman DI, Whittle S, Solowij N, Yücel M. Structural MRI findings in long-term cannabis users: what do we know? Substance use & misuse. [Research Support, Non-U.S. Gov't Review] 2010; 45(11): 1787-808.
13. Ashtari M, Avants B, Cyckowski L, et al. Medial temporal structures and memory functions in adolescents with heavy cannabis use. J Psychiatr Res 2011 Feb 4.
14. Medina KL, Nagel BJ, Tapert SF. Abnormal cerebellar morphometry in abstinent adolescent marijuana users. Psychiatry Res 2010 May 30; 182(2): 152-9.
15. Medina KL, Nagel BJ, Park A, McQueeny T, Tapert SF. Depressive symptoms in adolescents: associations with white matter volume and marijuana use. J Child Psychol Psychiatry 2007; 48(6): 592-600.
16. Wilson W, Mathew R, Turkington T, Hawk T, Coleman RE, Provenzale J. Brain morphological changes and early marijuana use. A MRI and PET study. J Addictive Diseases 2000; 19(1): 1-22.
17. Block RI, O'Leary DS, Ehrhardt JC, et al. Effects of frequent marijuana use on brain tissue volume and composition. NeuroReport 2000; 11(3): 491-6.
18. Kuehnle J, Mendelson JH, Davis KR, New PF. Computed tomographic examination of heavy marijuana smokers. JAMA 1977; 237(12): 1231-2.
19. Co BT, Goodwin DW, Gado M, Mickhael M, Hill SY. Absence of cerebral atrophy in chronic cannabis users. Evaluation by computerized transaxial tomography. JAMA 1977; 237(12): 1229-30.
20. Tzilos GK, Cintron CB, Wood JBR, et al. Lack of hippocampal volume change in long-term heavy cannabis users. Am J Addiction 2005; 14: 64-72.
21. Campbell AMG, Evans M, Thomson JLG, Williams MJ. Cerebral atrophy in young cannabis smokers. Lancet 1971; 2(7736): 1219-24.
22. Stefanis C. Biological aspects of cannabis use. In: Petersen R, editor. The International Challenge of Drug Abuse. Rockville, MD: National Institute on Drug Abuse; 1976; p: 149-78.
23. Hannerz J, Hindmarsh T. Neurological and neuroradiological examination of chronic cannabis smokers. Annals of Neurology 1983; 13(2): 207-10.
24. Medina KL, Schweinsburg AD, Cohen-Zion M, Nagel BJ, Tapert SF. Effects of alcohol and combined marijuana and alcohol use hippocampal volume and asymmetry. Neurotoxicol Teratol 2007; 29: 141-52.
25. Yücel M, Solowij N, Respondek C, et al. Regional brain abnormalities associated with heavy long-term cannabis use. Arch Gen Psychiatry 2008; 65(6): 1-8.
26. Solowij N, Yücel M, Respondek C, et al. Cerebellar white-matter changes in cannabis users with and without schizophrenia. Psychol Med 2011; 1-11.
27. Churchwell JC, Lopez-Larson M, Yurgelun-Todd DA. Altered frontal cortical volume and decision making in adolescent cannabis users. Frontiers in Psychology. [Original Research] 2010 2010-December-14; 1.
28. Mata I, Perez-Iglesias R, Roiz-Santianez R, et al. Gyrification brain abnormalities associated with adolescence and early-adulthood cannabis use. Brain Res 2010 Mar 4; 1317: 297-304.
29. Medina KL, McQueeny T, Nagel BJ, Hanson KL, Yang TT, Tapert SF. Prefrontal cortex morphometry in abstinent adolescent marijuana users: subtle gender effects. Addict Biol 2009 Sep; 14(4): 457-68.
30. Demirakca T, Sartorius A, Ende G, et al. Diminished gray matter in the hippocampus of cannabis users: Possible protective effects of cannabidiol. Drug Alcohol Depend 2011; 114(2-3): 242-5.
31. Jager G, Van Hell HH, De Win MML, et al. Effects of frequent cannabis use on hippocampal activity during an associative learning memory task. Eur Psychopharmacol 2007; 17: 289-97.
32. Matochik JA, Eldeth DA, Cadet DA, Bolla KI. Altered brain tissue composition in heavy marijuana users. Drug Alcohol Dependence 2005; 77: 23-30.
33. Lopez-Larson MP, Bogorodzki P, Rogowska J, et al. Altered prefrontal and insular cortical thickness in adolescent marijuana users. Behav Brain Res 2011; 220(1): 164-72.
34. Cousijn J, Wiers RW, Ridderinkhof KR, van den Brink W, Veltman DJ, Goudriaan AE. Grey matter alterations associated with cannabis use: Results of a VBM study in heavy cannabis users and healthy controls. NeuroImage 2011(In press).
35. McQueeny T, Padula CB, Price J, Medina KL, Logan P, Tapert SF. Gender effects on amygdala morphometry in adolescent marijuana users. Behavioural Brain Research. [doi: 10.1016/j.bbr.2011.05.031] 2011; 224(1): 128-34.
36. Clarke RC, Watson DP. Cannabis and the natural cannabis medicine. In: ElSohly MA, editor. Marijuana and the cannabinoids. New York: Humana Press; 2007. p. 1-15.
37. Hamilton M. A rating scale for depression. J Neurol Neurosurgical Psychiatry 1960; 23(1): 56-62.
38. Dell CA, Harrold B, Dell T. Test Review: Wilkinson, G. S., & Robertson, G. J. (2006). Wide Range Achievement Test'ÄîFourth Edition. Lutz, FL: Psychological Assessment Resources. WRAT4 Introductory Kit (includes manual, 25 test/response forms [blue and green], and accompanying test materials): $243.00. Rehabilitation Counseling Bulletin 2008 October 1, 2008; 52(1): 57-60.
39. Rey A. L'examen clinique en psychologie. Paris: Presses Universitaires de France; 1964.
40. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An Inventory for Measuring Depression. Archives General Psychiatry 1960; 4: 561-71.
41. Buschke H. Selective reminding for analysis of memory and learning. J Verbal Learning Verbal Behavior 1973; 12(5): 543-50.
42. Wechsler D. Wechsler Memory Scale. Corporation P, editor. San Antonio, TX1945.
43. Sivan AB. Benton Visual Retention Test: Fifth Edition. Corporation P, editor. San Antonio, TX1992.
44. Fornito A, Whittle S, Wood S, Velakoulis D, Pantelis C, Yücel M. The Influence of Sulcal Variability on Morphometry of the Human Anterior Cingulate and Paracingulate Cortex. NeuroImage 2006; 33: 843-54.
45. Fornito A, Wood SJ, Whittle S, et al. Variability of the paracingulate sulcus and morphometry of the medial frontal cortex: Associations with cortical thickness, surface area, volume, and sulcal depth. Human Brain Mapping 2008; 29(2): 222-36.
46. Yücel M, Stuart J, Maruff P, et al. Hemisferic and Gender-related Differences in the Gross Morphology of the Anterior Cingulate/Paracingulate Cortex in Normal Volunteers: An MRI Morphometric Study. Cerebral Cortex 2001; 11: 17-25.
47. Glass M, Faull RLM, Dragunow M. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77(2): 299.
48. Van Laere K, Goffin K, Casteels C, et al. Gender-dependent increases with healthy aging of the human cerebral cannabinoidtype 1 receptor binding using [18F]MK-9470 PET. NeuroImage. [doi: 10.1016/j.neuroimage.2007.10.053] 2008; 39(4): 1533-41.
49. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 1990; 87(5): 1932-6.
50. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 1998; 83(2): 393-411.
51. Marsicano G, Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 1999; 11(12): 4213-25.
52. Katona I, Rancz EA, Acsady L, et al. Distribution of CB1 Cannabinoid Receptors in the Amygdala and their Role in the Control of GABAergic Transmission. J Neurosci 2001; 21(23): 9506-18.
53. McDonald AJ, Mascagni F. Localization of the CB1 type cannabinoid receptor in the rat basolateral amygdala: high concentrations in a subpopulation of cholecystokinin-containing interneurons. Neuroscience 2001; 107(4): 641-52.
54. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 2002; 16(7): 1395-8.
55. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins, Leukotrienes and Essential Fatty Acids. [doi: 10.1054/plef.2001.0341] 2002; 66(2-3): 101-21.
56. Sim-Selley LJ. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Critical reviews in neurobiology. [Research Support, U.S. Gov't, P.H.S. Review] 2003; 15(2): 91-119.
57. Crippa JA, Zuardi AW, Martin-Santos R, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol 2009; 24(7): 515-23.
58. Sergerie K, Chochol C, Armony JL. The role of the amygdala in emotional processing: a quantitative meta-analysis of functional neuroimaging studies. Neuroscience and biobehavioral reviews. [Research Support, Non-U.S. Gov't Review] 2008; 32(4): 811-30.
59. Filbey FM, Schacht JP, Myers US, Chavez RS, Hutchison KE. Marijuana craving in the brain. Proc Natl Acad Sci 2009; 106(31): 13016-21.
60. Cousijn J, Goudriaan AE, Ridderinkhof KR, van den Brink W, Veltman DJ, Wiers RW. Neural responses associated with cuereactivity in frequent cannabis users. Addiction Biol 2012 Jan 20.
61. Harding IH, Solowij N, Harrison BJ, et al. Functional connectivity in brain networks underlying cognitive control in chronic cannabis users. Neuropsychopharmacology 2012; 37(8): 1923-33.
62. Jager G, Ramsey NF. Long-term consequences of adolescent cannabis exposure on the development of cognition, brain structure and function: an overview of animal and human research. Curr Drug Abuse Rev 2008; 1(2): 114-23.
63. Martin-Santos R, Fagundo AB, et al. Neuroimaging in cannabis use: a systematic review of the literature. Psychol Med 2010; 40(3): 383-98.
64. Chang L, Chronicle EP. Functional imaging studies in cannabis users. Neuroscientist 2007; 13(5): 422-32.
65. Quickfall J, Crockford D. Brain neuroimaging in cannabis use: a review. J Neuropsychiatry Clin Neurosci 2006; 18(3): 318-32.
66. Viveros MP, Marco EM, Llorente R, Lamota L. The role of the hippocampus in mediating emotional responses to nicotine and cannabinoids: a possible neural substrate for functional interactions. Behavioural pharmacology. [Research Support, Non-U.S. Gov't Review] 2007; 18(5-6): 375-89.
67. Roohbakhsh A, Keshavarz S, Hasanein P, Rezvani ME, Moghaddam AH. Role of Endocannabinoid System in the Ventral Hippocampus of Rats in the Modulation of Anxiety-Like Behaviours. Basic Clin Pharmacol Toxicol 2009; 105(5): 333-8.
68. Garcia-Gutierrez MS, Manzanares J. Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice. J Psychopharmacol 2011; 25(1): 111-20.
69. Tan H, Lauzon NM, Bishop SF, Bechard MA, Laviolette SR. Integrated cannabinoid CB1 receptor transmission within the amygdala-prefrontal cortical pathway modulates neuronal plasticity and emotional memory encoding. Cereb Cortex 2010; 20(6): 1486-96.
70. Somaini L, Manfredini M, Amore M, Zaimovic A, Raggi MA, Leonardi C, et al. Psychobiological responses to unpleasant emotions in cannabis users. European archives of psychiatry and clinical neuroscience 2012; 262(1): 47-57.
71. Marsicano G, Wojtak C, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418: 530-4.
72. Lafenetre P, Chaouloff F, Marsicano G. The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction. Pharmacol Res 2007; 56(5): 367-81.
73. Ashton JC, Darlington CL, Smith PF. Co-distribution of the cannabinoid CB1 receptor and the 5-HT transporter in the rat amygdale. European J pharmacology. [Research Support, Non-U.S. Gov't] 2006; 537(1-3): 70-1.
74. Everitt BJ, Cador M, Robbins TW. Interactions between the amygdala and ventral striatum in stimulus-reward associations: studies using a second-order schedule of sexual reinforcement. Neuroscience 1989; 30(1): 63-75.
75. Everitt BJ, Parkinson JA, Olmstead MC, Arroyo M, Robledo P, Robbins TW. Associative Processes in Addiction and Reward The Role of Amygdala-Ventral Striatal Subsystems. Ann New York Acad Sci 1999; 877(1): 412-38.
76. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana use. Neurology 2002; 59(9): 1337-43.
77. Pope HG, Jr. Cannabis, cognition, and residual confounding. JAMA: the J the American Medical Association. [Comment Editorial Research Support, U.S. Gov't, P.H.S.] 2002; 287(9): 1172-4.
78. Scallet AC. Neurotoxicology of cannabis and THC: A review of chronic exposure studies in animals. Pharmacology Biochemistry and Behavior. [doi: 10.1016/0091-3057(91)90380-K] 1991; 40(3): 671-6.
79. Ongur D, Price JL. The organization of networks within the orbital and medial prefrontal cortex of rats, monkeys and humans. Cerebral cortex. [Research Support, U.S. Gov't, P.H.S. Review] 2000; 10(3): 206-19.
80. Giedd JN, Blumenthal J, Jeffries NO, et al. Brain development during childhood and adolescence: a longitudinal MRI study. Nature Neuroscience 1999; 2(10): 861-3.
81. Berghuis P, Rajnicek AM, Morozov YM, et al. Hardwiring the Brain: Endocannabinoids Shape Neuronal Connectivity. Sci 2007; 316(5828): 1212-6.
82. Lange N, Giedd JN, Castellanos FX, Vaituzis AC, Rapaport JL. Variability of human brain structure size: ages 4-20 years. Psychiatry Res: Neuroimaging Section 1997; 74: 1-12.
83. Rubino T, Vigano D, Realini N, et al. Chronic delta 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. Neuropsychopharmacology. [Comparative Study Research Support, Non-U.S. Gov't] 2008; 33(11): 2760-71.
84. Rubino T, Realini N, Braida D, et al. The Depressive Phenotype Induced in Adult Female Rats by Adolescent Exposure to THC is Associated with Cognitive Impairment and Altered Neuroplasticity in the Prefrontal Cortex. Neurotoxicity Res 2009; 15(4): 291-302.
85. Winsauer PJ, Daniel JM, Filipeanu CM, et al. Long-term behavioral and pharmacodynamic effects of delta-9-tetrahydrocannabinol in female rats depend on ovarian hormone status. Addict Biol 2011; 16(1): 64-81.
86. Burston JJ, Wiley JL, Craig AA, Selley DE, Sim-Selley LJ. Regional enhancement of cannabinoid CB1 receptor desensitization in female adolescent rats following repeated Deltatetrahydrocannabinol exposure. Br J Pharmacol 2010; 161(1): 103-12.
87. Moore TH, Zammit S, Lingford-Huges A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319-28.
88. Skinner R, Conlon L, Gibbons D, McDonald C. Cannabis use and non-clinical dimensions of psychosis in university students presenting to primary care. Acta Psychiatrica Scandinavica 2011; 123(1): 21-7.
89. Huizink AC, Ferdinand RF, Ormel J, Verhulst FC. Hypothalamicpituitary-adrenal axis activity and early onset of cannabis use. Addiction 2006; 101: 1581-8.
90. King GR, Ernst T, Deng W, et al. Altered Brain Activation During Visuomotor Integration in Chronic Active Cannabis Users: Relationship to Cortisol Levels. J Neurosci 2011; 31(49): 17923-31.
91. Pariante CM. Depression, Stress and the Adrenal Axis. Neuroendocrinology 2003; 15(8): 811-2.
92. Pariante CM, Dazzan P, Danese A, et al. Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study. Neuropsychopharmacology. [Clinical Trial Comparative Study Controlled Clinical Trial Research Support, Non-U.S. Gov't] 2005; 30(10): 1923-31.
93. Pariante CM, Vassilopoulou K, Velakoulis D, et al. Pituitary volume in psychosis. Br J Psychiatry 2004; 185(1): 5-10.
94. Colzato LS, Hommel B. Cannabis, cocaine, and visuomotor integration: evidence for a role of dopamine D1 receptors in binding perception and action. Neuropsychologia 2008; 46(5): 1570-5.
95. Degenhardt L, Hall W. Is cannabis use a contributory cause of psychosis? Can J Psychiatry 2006; 51(9): 556-65.
96. Degenhardt L, Hall W, Lynskey M. Exploring the association between cannabis use and depression. Addiction 2003; 98: 1493-504.
97. Tait RJ, Mackinnon A, Christensen H. Cannabis use and cognitive function: Eight year trajectory in a young adult cohort. Addiction 2011; Postprint.
98. Cohen M, Solowij N, Carr V. Cannabis, cannabinoids and schizophrenia: integration of the evidence. Australian New Zealand J Psychiatry 2008; 42(5): 357-68.
99. Solowij N, Jones KA, Rozman ME, et al. Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. Psychopharmacology (Berl) 2011 Feb 17.
100. Kanayama G, Rogowska J, Pope H, Gruber SA, Yurgelun-Todd DA. Spatial working memory in heavy cannabis users: a functional magnetic resonance imaging study. Psychopharmacology 2004; 176: 239-47.
101. Nestor L, Roberts G, Garavan H, Hester R. Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users. NeuroImage. [Research Support, N.I.H., Extramural] 2008; 40(3): 1328-39.
102. Rais M, Cahn W, Van Haren N, et al. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am J Psychiatry. [Comparative Study] 2008; 165(4): 490-6.
103. Bangalore SS, Prasad KM, Montrose DM, Goradia DD, Diwadkar VA, Keshavan MS. Cannabis use and brain structural alterations in first episode schizophrenia--a region of interest, voxel based morphometric study. Schizophr Res. [Research Support, N.I.H., Extramural] 2008; 99(1-3): 1-6.
104. Rais M, van Haren NE, Cahn W, et al. Cannabis use and progressive cortical thickness loss in areas rich in CB1 receptors during the first five years of schizophrenia. Eur Neuropsychopharmacol. [Comparative Study] 2010; 20(12): 855-65.
105. Stone JM, Bhattacharyya S, Barker GJ, McGuire PK. Substance use and regional gray matter volume in individuals at high risk of psychosis. Eur Neuropsychopharmacol. [Randomized Controlled Trial Research Support, Non-U.S. Gov't] 2012; 22(2): 114-22.
106. Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res. [Case Reports Research Support, Non-U.S. Gov't] 2001; 107(3): 173-7.
107. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the Effect of Adolescent-Onset Cannabis Use on Adult Psychosis by a Functional Polymorphism in the Catechol-O-Methyltransferase Gene: Longitudinal Evidence of a Gene X Environment Interaction. Biol Psychiatry 2005; 57: 1117-27.
108. van Winkel R. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry. [Research Support, Non-U.S. Gov't] 2011; 68(2): 148-57.
109. van Winkel R, van Beveren NJ, Simons C. AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology. [Comparative Study Research Support, Non-U.S. Gov't] 2011; 36(12): 2529-37.
110. Bhattacharyya S, Atakan Z, Martin-Santos R, et al. Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of delta-9-tetrahydrocannabinol on midbrain and striatal function. Mol Psychiatry. [Letter Research Support, Non-U.S. Gov't] 2012; 17(12): 1152-5.
111. Di Forti M, Iyegbe C, Sallis H, et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry. [Research Support, Non-U.S. Gov't] 2012; 72(10): 811-6.
112. Henquet C, Rosa A, Krabbendam L, et al. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology. [Randomized Controlled Trial Research Support, Non-U.S. Gov't] 2006; 31(12): 2748-57.
113. Sullivan JM. Cellular and molecular mechanisms underlying learning and memory impairments produced by cannabinoids. Learning & memory. [Research Support, U.S. Gov't, P.H.S. Review] 2000; 7(3): 132-9.
114. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 2002; 296(5568): 678-82.
115. Δ9-Tetrahydrocannabinol Treatment Produces a Time-Dependent Loss of Cannabinoid Receptors and Cannabinoid Receptor-Activated G Proteins in Rat Brain. J Neurochem 1999; 73(6): 2447-59.
116. Downer E, Boland B, Fogarty M, Campbell VCA. Delta-9-Tetrahydrocannabinol iinduces the apoptotic pathway in cultured cortical neurons via activation of the CB1 receptor. NeuroReport 2001; 12(18): 3973-8.
117. Harper JW, Heath RG, Myers WA. Effects of Cannabis sativa on ultrastructure of the synapse in monkey brain. J Neuroscience Res 1977; 3(2): 87-93.
118. Kolb B, Gorny G, Limebeer CL, Parker LA. Chronic treatment with Delta-9-tetrahydrocannabinol alters the structure of neurons in the nucleus accumbens shell and medial prefrontal cortex of rats. Synapse 2006; 60(6): 429-36.
119. Δ9-Tetrahydrocannabinol. The J Neuroscience 1998; 18(14): 5322-32.
120. Mato S, Chevaleyre V, Robbe D, Pazos A, Castillo PE, Manzoni OJ. A single in-vivo exposure to delta 9THC blocks endocannabinoid-mediated synaptic plasticity. Nat Neurosci 2004; 7(6): 585-6.
121. Robbe D, Buzsaki G. Alteration of theta timescale dynamics of hippocampal place cells by a cannabinoid is associated with memory impairment. J Neurosci 2009; 29(40): 12597-605.
122. Robbe D, Montgomery SM, Thome A, Rueda-Orozco PE, McNaughton BL, Buzsaki Gr. Cannabinoids reveal importance of spike timing coordination in hippocampal function. Nature Neurosci 2006; 9(12): 1526-33.
123. Heath RG. Marijuana: effects on deep and surface electroencephalograms of rhesus monkeys. Neuropharmacology 1973; 12(1): 1-14.
124. Heath RG. Cannabis sativa derivates: Effects on brain function of monkeys. In: Nahas GG, editor. Marihuana: Chemistry, Biochemistry and Cellular Effects. New York: Springer-Verlag; 1976; p. 507-19.
125. Δ9-THC: Acute and chronic effects on brain function of monkeys. In: Brande MC, Szara S, editors. Pharmacology of Marihuana. New York: Raven Press 1976; p. 345-56.
126. Azad SC, Eder M, Marsicano G, Lutz B, Zieglgnsberger W, Rammes G. Activation of the Cannabinoid Receptor Type 1 Decreases Glutamatergic and GABAergic Synaptic Transmission in the Lateral Amygdala of the Mouse. Learning Memory 2003; 10(2): 116-28.
127. Azad SC, Monory K, Marsicano G, et al. Circuitry for Associative Plasticity in the Amygdala Involves Endocannabinoid Signaling. J Neurosci 2004; 24(44): 9953-61.
128. Skosnik PD, Krishnan GP, Aydt EE, Kuhlenshmidt HA, O'Donnell BF. Psychophysiological evidence of altered neural synchronization in cannabis use: relationship to schizotypy. The American J psychiatry. [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't] 2006; 163(10): 1798-805.
129. Diana MA, Levenes C, Mackie K, Marty A. Short-term retrograde inhibition of GABAergic synaptic currents in rat Purkinje cells is mediated by endogenous cannabinoids. The J neuroscience: the official J the Society for Neuroscience. [In vitro Research Support, Non-U.S. Gov't] 2002; 22(1): 200-8.
130. Ashton JC, Appleton I, Darlington CL, Smith PF. Immunohistochemical localization of cannabinoid CB1 receptor in inhibitory interneurons in the cerebellum. Cerebellum. [Comparative Study Research Support, Non-U.S. Gov't] 2004; 3(4): 222-6.
131. Breivogel CS, Walker JM, Huang SM, Roy MB, Childers SR. Cannabinoid signaling in rat cerebellar granule cells: G-protein activation, inhibition of glutamate release and endogenous cannabinoids. Neuropharmacology. [Research Support, U.S. Gov't, P.H.S.] 2004; 47(1): 81-91.
132. Daniel H, Rancillac A, Crepel F. Mechanisms underlying cannabinoid inhibition of presynaptic Ca2+ influx at parallel fibre synapses of the rat cerebellum. The J physiology. [In vitro Research Support, Non-U.S. Gov't] 2004; 557(Pt 1): 159-74.
133. Kawamura Y, Fukaya M, Maejima T, et al. The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. The J neuroscience: the official J the Society for Neuroscience. [Comparative Study Research Support, Non-U.S. Gov't] 2006; 26(11): 2991-3001.
134. Verrico CD, Jentsch JD, Roth RH. Persistent and anatomically selective reduction in prefrontal cortical dopamine metabolism after repeated, intermittent cannabinoid administration to rats. Synapse. [Research Support, U.S. Gov't, P.H.S.] 2003; 49(1): 61-6.
135. Jentsch JD, Verrico CD, Le D, Roth RH. Repeated exposure to delta 9-tetrahydrocannabinol reduces prefrontal cortical dopamine metabolism in the rat. Neuroscience letters. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 1998; 246(3): 169-72.
136. Loeber RT, Yurgelun-Todd DA. Human neuroimaging of acute and chronic marijuana use: implications for frontocerebellar dysfunction. Human Psychopharmacology: Clinical & Experimental. [Article] 1999; 14(5): 291-304.
137. Kuehl FA, Jr., Egan RW. Prostaglandins, arachidonic acid, and inflammation. Science. [Review] 1980; 210(4473): 978-84.
138. Tang DG, Chen YQ, Honn KV. Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proceedings of the National Academy of Sciences of the United States of America. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 1996; 93(11): 5241-6.
139. Chen Q, Galleano M, Cederbaum AI. Cytotoxicity and apoptosis produced by arachidonic acid in Hep G2 cells overexpressing human cytochrome P4502E1. J Biological Chem [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 1997; 272(23): 14532-41.
140. Li Y, Maher P, Schubert D. A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 1997; 19(2): 453-63.
141. Wissing D, Mouritzen H, Egeblad M, Poirier GG, Jaattela M. Involvement of caspase-dependent activation of cytosolic phospholipase A2 in tumor necrosis factor-induced apoptosis. Proc Natl Acad Sci USA. [Research Support, Non-U.S. Gov't] 1997; 94(10): 5073-7.
142. Herman JP, Figueiredo H, Mueller NK, et al. Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness. Frontiers in Neuroendocrinology. [doi: 10.1016/j.yfrne.2003.07.001] 2003; 24(3): 151-80.
143. Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J psychosomatic research. [Review] 2002; 53(4): 865-71.
144. D'Souza D, Pittman B, Perry E, Simen A. Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. Psychopharmacology 2009; 202(4): 569-78.
145. Sano K, Koushi E, Irie K, et al. Delta(9)-tetrahydrocannabinol Enhances an Increase of Plasma Corticosterone Levels Induced by Forced Swim-Stress. Biological & Pharmaceutical Bulletin 2009; 32(12): 2065-7.
146. Arevalo C, de Miguel R, Hernndez-Tristn R. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacology Biochemistry and Behavior. [doi: 10.1016/S0091-3057(01)00578-0] 2001; 70(1): 123-31.
147. Mazzocchi G, Andreis PG, De Caro R, Aragona F, Gottardo L, Nussdorfer GG. Cerebellin enhances in vitro secretory activity of human adrenal gland. The J clinical endocrinology and metabolism. [In vitro] 1999; 84(2): 632-5.
148. Teicher MH, Andersen SL, Polcari A, Anderson CM, Navalta CP, Kim DM. The neurobiological consequences of early stress and childhood maltreatment. Neuroscience and Biobehavioral Reviews. [Research Support, U.S. Gov't, P.H.S. Review] 2003; 27(1-2): 33-44.
149. Charles Eldridge J, Landfield PW. Cannabinoid interactions with glucocorticoid receptors in rat hippocampus. Brain Research. [doi: DOI: 10.1016/0006-8993(90)90123-S] 1990; 534(1-2): 135-41.
150. Hill MN, Gorzalka BB. Increased sensitivity to restraint stress and novelty-induced emotionality following long-term, high dose cannabinoid exposure. Psychoneuroendocrinology 2006; 31(4): 526-36.
151. Cota D, Steiner MA, Marsicano G, et al. Requirement of Cannabinoid Receptor Type 1 for the Basal Modulation of Hypothalamic-Pituitary-Adrenal Axis Function. Endocrinology 2007; 148(4): 1574-81.
152. Rodriguez de Fonseca F, Carrera MR, Navarro M, Koob GF, Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 1997; 276(5321): 2050-4.
153. Ganon-Elazar E, Akirav I. Cannabinoid receptor activation in the basolateral amygdala blocks the effects of stress on the conditioning and extinction of inhibitory avoidance. The J neuroscience: the official J the Society for Neuroscience. [Comparative Study Research Support, Non-U.S. Gov't] 2009; 29(36): 11078-88.
154. Berrendero F, Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology. [Research Support, Non-U.S. Gov't] 2002; 163(1): 111-7.
155. Kathuria S, Gaetani S, Fegley D, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nature medicine. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 2003; 9(1): 76-81.
156. Cota D. The role of the endocannabinoid system in the regulation of hypothalamic-pituitary-adrenal axis activity. J Neuroendocrinol 2008; 20 Suppl 1: 35-8.
157. Giuliani D, Ferrari F, Ottani A. The cannabinoid agonist HU 210 modifies rat behavioural responses to novelty and stress. Pharmacological research: the official J the Italian Pharmacological Society. [Research Support, Non-U.S. Gov't] 2000 Jan; 41(1): 47-53.
158. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. BMJ 2002 23; 325(7374): 1195-8.
159. O'Shea M, Singh ME, McGregor IS, Mallet PE. Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. J psychopharmacology. [Research Support, Non-U.S. Gov't] 2004; 18(4): 502-8.
160. Kallen VL, Tulen JHM, Utens EMWJ, Treffers PDA, De Jong FH, Ferdinand RF. Associations between HPA axis functioning and level of anxiety in children and adolescents with an anxiety disorder. Depression Anxiety 2008; 25(2): 131-41.
161. Landgraf, Wigger, Holsboer, Neumann. Hyper-Reactive Hypothalamo-Pituitary-Adrenocortical Axis in Rats Bred for High Anxiety-Related Behaviour. J Neuroendocrinol 1999; 11(6): 405-7.
162. MacPherson A, Dinkel K, Sapolsky R. Glucocorticoids worsen excitotoxin-induced expression of pro-inflammatory cytokines in hippocampal cultures. Experimental neurology. [Research Support, Non-U.S. Gov't] 2005; 194(2): 376-83.
163. Sapolsky RM, Pulsinelli WA. Glucocorticoids potentiate ischemic injury to neurons: therapeutic implications. Science. [Research Support, U.S. Gov't, P.H.S.] 1985; 229(4720): 1397-400.
164. Davidson RJ, Pizzagalli DA, Nitschke JB, Putnam K. Depression: Perspectives from Affective Neuroscience. Annual Review of Psychology 2002; 53: 545-74.
165. Lorenzetti V, Allen NB, Fornito A, Yücel M. Structural brain abnormalities in major depressive disorder: a selective review of recent MRI studies. J affective disorders. [Research Support, Non-U.S. Gov't Review] 2009; 117(1-2): 1-17.
166. Diana M, Melis M, Muntoni AL, Gessa GL. Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci USA 1998; 95(17): 10269-73.
167. Wenger T, Moldrich G, Furst S. Neuromorphological background of cannabis addiction. Brain Res Bullettin 2003; 61: 125-8.
168. van Hell HH, Vink M, Ossewaarde L, Jager G, Kahn RS, Ramsey NF. Chronic effects of cannabis use on the human reward system: An fMRI study. European neuropsychopharmacology: the J Eur College Neuropsychopharmacol 2010; 20(3): 153-63.
169. Martin-Soelch C, Kobel M, Stoecklin M, et al. Reduced response to reward in smokers and cannabis users. Neuropsychobiology 2009; 60(2): 94-103.
170. Martin-Soelch C, Missimer J, Leenders KL, Schultz W. Neural activity related to the processing of increasing monetary reward in smokers and nonsmokers. The European J neuroscience. [Research Support, Non-U.S. Gov't] 2003; 18(3): 680-8.
171. Pistis M, Perra S, Pillolla G, Melis M, Muntoni AL, Gessa GL. Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biol Psychiatry. [Comparative Study Research Support, Non-U.S. Gov't] 2004; 56(2): 86-94.
172. Melis M, Spiga S, Diana M. The dopamine hypothesis of drug addiction: hypodopaminergic state. International review of neurobiology. [Research Support, Non-U.S. Gov't Review] 2005; 63: 101-54.
173. Koob GF. Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review] 2009; 56 Suppl 1: 18-31.
174. Kelley AE, Domesick VB, Nauta WJ. The amygdalostriatal projection in the rat-an anatomical study by anterograde and retrograde tracing methods. Neuroscience. [Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.] 1982; 7(3): 615-30.
175. Berendse HW, Galis-de Graaf Y, Groenewegen HJ. Topographical organization and relationship with ventral striatal compartments of prefrontal corticostriatal projections in the rat. J Comparative Neurol 1992; 316(3): 314-47.
176. Groenewegen HJ, Vermeulen-Van der Zee E, te Kortschot A, Witter MP. Organization of the projections from the subiculum to the ventral striatum in the rat. A study using anterograde transport of Phaseolus vulgaris leucoagglutinin. Neuroscience 1987; 23(1): 103-20.
177. Cador M, Robbins TW, Everitt BJ. Involvement of the amygdala in stimulus-reward associations: interaction with the ventral striatum. Neuroscience 1989; 30(1): 77-86.
178. Gaffan D. Amygdala and the memory of reward. In: Aggleton JP, editor. The AMygdala: Neurobiological aspects of Emotion. New York: Wiley 1992; p. 471-83.
179. Muramoto ML, Leshan L. Adolescent substance abuse. Recognition and early intervention. Primary care. [Review] 1993; 20(1): 141-54.
180. Wise RA. Dopamine and food reward: back to the elements. American J physiology Regulatory, integrative and comparative physiology. [Comment Editorial] 2004; 286(1): R13.
181. Lansink CS, Goltstein PM, Lankelma JV, McNaughton BL, Pennartz CMA. Hippocampus Leads Ventral Striatum in Replay of Place-Reward Information. PLoS Biol 2009; 7(8): e1000173.
182. Kelley AE, Domesick VB. The distribution of the projection from the hippocampal formation to the nucleus accumbens in the rat: an anterograde-and retrograde-horseradish peroxidase study. Neuroscience. [Comparative Study Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.] 1982; 7(10): 2321-35.
183. Martin BR, Sim-Selley LJ, Selley DE. Signaling pathways involved in the development of cannabinoid tolerance. Trends in Pharmacological Sciences 2004; 25(6): 325-30.
184. Thoma P, Bellebaum C, Koch B, Schwarz M, Daum I. The cerebellum is involved in reward-based reversal learning. Cerebellum. [Research Support, Non-U.S. Gov't] 2008; 7(3): 433-43.
185. Viveros MP, Marco EM, Llorente R, Lopez-Gallardo M. Endocannabinoid system and synaptic plasticity: implications for emotional responses. Neural plasticity. [Review] 2007; 2007: 52908.
186. Dorard G, Berthoz S, Phan O, Corcos M, Bungener C. Affect dysregulation in cannabis abusers: a study in adolescents and young adults. Eur Child Adolesc Psychiatry 2008; 17(5): 274-82.
187. Gardner E. Brain reward mechanisms. In: Lowinson J, Ruiz P, Millman R, Langrod J, editors. Substance Abuse: A Comprehensive Textbook. 3rd ed. Baltimore: Williams & Wilkins; 1997.
188. Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception I: The neural basis of normal emotion perception. Biol Psychiatry. [Review] 2003; 54(5): 504-14.
189. Schutter DJ, van Honk J. The cerebellum on the rise in human emotion. Cerebellum. [Research Support, Non-U.S. Gov't Review] 2005; 4(4): 290-4.
190. Phan KL, Angstadt M, Golden J, Onyewuenyi I, Popovska A, de Wit H. Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. J Neurosci 2008; 28(10): 2313-9.
191. Gruber SA, Rogowska J, Yurgelun-Todd DA. Altered affective response in marijuana smokers: An FMRI study. Drug and Alcohol Dependence. [doi: 10.1016/j.drugalcdep.2009.06.019] 2009; 105(1-2): 139-53.
192. Fusar-Poli P. Distinct effects of D9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. European Psychiatry. [doi: 10.1016/S0924-9338(09)70439-0] 2009; 24(Supplement 1): S206-S.
193. Bhattacharyya S, Fusar-Poli P, Borgwardt S, et al. Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry 2009; 66(4): 442-51.
194. Fusar-Poli P, Allen P, Bhattacharyya S, et al. Modulation of effective connectivity during emotional processing by delta-9-tetrahydrocannabinol and cannabidiol. The International J Neuropsychopharmacology 2010; 13(04): 421-32.
195. Velakoulis D, Pantelis C, McGorry PD, et al. Hippocampal volume in first-episode psychoses and chronic schizophrenia: a highresolution magnetic resonance imaging study. Arch Gen Psychiatry 1999; 56(2): 133-41.
196. Velakoulis D, Wood SJ, Wong MTH, et al. Hippocampal and Amygdala Volumes According to Psychosis Stage and Diagnosis: A Magnetic Resonance Imaging Study of Chronic Schizophrenia, First-Episode Psychosis, and Ultra-High-Risk Individuals. Arch Gen Psychiatry 2006; 63(2): 139-49.
197. Videbech P, Petersen TH. Depression, Stress and Brain Function. Ugeskr Laeger 2001; 163(47): 6568-72.
198. Campbell S, Marriott M, Nahmias C, MacQueen GM. Lower hippocampal volume in patients suffering from depression: a metaanalysis. The American J psychiatry. [Meta-Analysis Research Support, Non-U.S. Gov't] 2004; 161(4): 598-607.
199. Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. The American J psychiatry. [Comparative Study Meta-Analysis] 2004; 161(11): 1957-66.
200. Brambilla P, Barale F, Caverzasi E, Soares JC. Anatomical MRI findings in mood and anxiety disorders. Epidemiologia e psichiatria sociale. [Research Support, Non-U.S. Gov't Review] 2002; 11(2): 88-99.
201. Soares JC, Mann JJ. The Anatomy of Mood Disorders - Review of Structural Neuroimaging Studies. Biol Psychiatry 1997; 41: 86-106.
202. Yücel M, Lubman DI. Neurocognitive and neuroimaging evidence of behavioural dysregulation in human drug addiction: implications for diagnosis, treatment and prevention. Drug Alcohol Rev 2007; 26(1): 33-9.
203. Buchan BJ, Dennis ML, Tims FM, Diamond GS. Cannabis use: consistency and validity of self-report, on-site urine testing and laboratory testing. Addiction 2002; 97: 98.
204. Harrison L. The validity of self-reported drug use in survey research: an overview and critique of research methods. NIDA research monograph. [Review] 1997; 167: 17-36.
205. Harrison LD. The Validity of Self-Reported Drug Use Among Arrestees. 41st meeting Am Soc Criminol 1989; Reno1989.
206. National Institute of Justice. DUF: 1988 Drug Use Forecasting Annual Report. Washington, DC: National Institute of Justice1990.
207. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. [Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't] 2010; 35(3): 764-74.
208. Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenialike symptoms in people who use cannabis. Br J Psychiatry. [Research Support, Non-U.S. Gov't] 2008; 192(4): 306-7.
209. Morgan CJ, Freeman TP, Schafer GL, Curran HV. Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology. [Clinical Trial Research Support, Non-U.S. Gov't] 2010; 35(9): 1879-85.
210. Morgan CJ, Schafer G, Freeman TP, Curran HV. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. Br J Psychiatry. [Research Support, Non-U.S. Gov't] 2010; 197(4): 285-90.
211. Pope HG, Jr., Gruber AJ, Yurgelun-Todd D. Residual neuropsychologic effects of cannabis. Current psychiatry reports. [Research Support, U.S. Gov't, P.H.S. Review] 2001; 3(6): 507-12.
212. Fried P, Watkinson B, James D, Gray R. Current and former marijuana use: preliminary findings of a longitudinal study of effects on IQ in young adults. Canadian Med Assoc J 2002; 166(7): 887-91.
213. Fried PA, Watkinson B, Gray R. Neurocognitive consequences of marihuana--a comparison with pre-drug performance. Neurotoxicology and teratology. [Comparative Study] 2005; 27(2): 231-9.
214. APA APA. DSM-IV Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition 1996.
215. Tisserand DJ, Pruessner JC, Sanz Arigita EJ, et al. Regional Frontal Cortical Volumes Decrease Differentially in Aging: An MRI Study to Compare Volumetric Approaches and Voxel-Based Morphometry. NeuroImage. [doi: DOI: 10.1006/nimg.2002.1173] 2002; 17(2): 657-69.
216. Ono M, Kubik S, Abernathy CD. Atlas of the cerebral sulci 1990.
217. Rodriguez De Fonseca F, Gorriti MA, Fernandez-Ruiz JJ, Palomo T, Ramos JA. Downregulation of rat brain cannabinoid binding sites after chronic delta-9-tetrahydrocannabinol treatment. Pharmacology Biochemistry and Behavior 1994; 47(1): 33-40.
218. Romero J, Garcia-Palomero E, Castro JG, Garcia-Gil L, Ramos JA, Fernandez-Ruiz JJ. Effects of chronic exposure to deltatetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Molecular Brain Res 1997; 46(1-2): 100-8.
219. Zhuang S-y, Kittler J, Grigorenko EV, et al. Effects of long-term exposure to delta-9-THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions. Molecular Brain Res 1998; 62(2): 141-9.
220. Moldrich G, Wenger T. Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides. [Research Support, Non-U.S. Gov't] 2000; 21(11): 1735-42.
221. Bossong MG, Van Berckel BNM, Boellaard R, et al. A9-Tetrahydrocannabinol Induces Dopamine Release in the Human Striatum. Basingstoke, ROYAUME-UNI: Nature Publishing Group; 2009.
222. Nagai M, Kishi K, Kato S. Insular cortex and neuropsychiatric disorders: a review of recent literature. European psychiatry: the J the Association of European Psychiatrists. [Review] 2007; 22(6): 387-94.
223. van Hell HH, Bossong MG, Jager G, et al. Evidence for involvement of the insula in the psychotropic effects of THC in humans: a double-blind, randomized pharmacological MRI study. The international J neuropsychopharmacology / official scientific J the Collegium Internationale Neuropsychopharmacologicum 2011; 14(10): 1377-88.
224. Nestor L, Hester R, Garavan H. Increased ventral striatal BOLD activity during non-drug reward anticipation in cannabis users. NeuroImage. [Research Support, N.I.H., Extramural] 2010; 49(1): 1133-43.
225. Schweinsburg AD, Schweinsburg BC, Medina KL, McQueeny T, Brown SA, Tapert SF. The influence of recency of use on fMRI response during spatial working memory in adolescent marijuana users. J Psychoactive Drugs 2010; 42(3): 401-12.
226. Mufson EJ, Mesulam MM, Pandya DN. Insular interconnections with the amygdala in the rhesus monkey. Neuroscience. [Research Support, U.S. Gov't, P.H.S.] 1981; 6(7): 1231-48.
227. Phelps EA, O'Connor KJ, Gatenby JC, Gore JC, Grillon C, Davis M. Activation of the left amygdala to a cognitive representation of fear. Nature neuroscience. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 2001; 4(4): 437-41.
228. Paulus MP, Stein MB. An insular view of anxiety. Biol Psychiatry. [Review] 2006; 60(4): 383-7.
229. Etkin A, Wager TD. Functional neuroimaging of anxiety: a metaanalysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. The American J Psychiatry. [Comparative Study Meta-Analysis] 2007; 164(10): 1476-88.
230. Thayer JF, Lane RD. A model of neurovisceral integration in emotion regulation and dysregulation. J affective disorders. [Review] 2000; 61(3): 201-16.
231. Phillips ML. Understanding the neurobiology of emotion perception: implications for psychiatry. The British J psychiatry: the J mental science. [Editorial] 2003; 182: 190-2.
232. Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception II: Implications for major psychiatric disorders. Biol Psychiatry. [Review] 2003; 54(5): 515-28.
233. Takahashi T, Yücel M, Lorenzetti V, et al. Volumetric MRI study of the insular cortex in individuals with current and past major depression. J affective disorders. [Research Support, Non-U.S. Gov't] 2010; 121(3): 231-8.
234. van Leeuwen AP, Creemers HE, Greaves-Lord K, Verhulst FC, Ormel J, Huizink AC. Hypothalamic-pituitary-adrenal axis reactivity to social stress and adolescent cannabis use: the TRAILS study. Addiction 2011; 106(8): 1484-92.
235. Ranganathan M, Braley G, Pittman B, et al. The effects of cannabinoids on serum cortisol and prolactin in humans. Psychopharmacology. [Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't] 2009; 203(4): 737-44.
236. Hill MN, Gorzalka BB. Enhancement of anxiety-like responsiveness to the cannabinoid CB1 receptor agonist HU-210 following chronic stress. European J Pharmacology 2004; 499(3): 291-5.
237. Valjent E, Mitchell JM, Besson M-J, Caboche J, Maldonado R. Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol 2002; 135(2): 564-78.
238. Thomas H. Psychiatric symptoms in cannabis users. The British J psychiatry: the J mental science. [Review] 1993; 163: 141-9.
239. Hall W, Degenhardt L. Cannabis use and the risk of developing a psychotic disorder. World Psychiatry 2008; 7(2): 68-71.
240. Hall W, Degenhardt L. Prevalence and correlates of cannabis use in developed and developing countries. Curr Opin Psychiatry 2007; 20(4): 393-7.
241. Hall WD. Cannabis use and the mental health of young people. Aust N Z J Psychiatry 2006; 40(2): 105-13.
242. Takahashi T, Suzuki M, Velakoulis D, et al. Increased pituitary volume in schizophrenia spectrum disorders. Schizophrenia research. [Research Support, Non-U.S. Govt] 2009; 108(1-3): 114-21.
243. Axelson DA, Doraiswamy PM, Boyko OB, et al. In vivo assessment of pituitary volume with magnetic resonance imaging and systematic stereology: relationship to dexamethasone suppression test results in patients. Psychiatry research. [Research Support, U.S. Gov't, P.H.S.] 1992; 44(1): 63-70.
244. Krishnan KRR, Doraiswamy PM, Lurie SN, et al. Pituitary Size in Depression. J Clinical Endocrinology & Metabolism 1991; 72(2): 256-9.
245. Garner B, Pariante CM, Wood SJ, et al. Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis. Biol Psychiatry. [Comparative Study Research Support, Non-U.S. Gov't] 2005; 58(5): 417-23.
246. MacMaster FP, Kusumakar V. MRI study of the pituitary gland in adolescent depression. J psychiatric research. [Research Support, Non-U.S. Gov't] 2004; 38(3): 231-6.
247. Cheetham A, Allen NB, Whittle S, Simmons J, Yücel M, Lubman DI. Orbitofrontal Volumes in Early Adolescence Predict Initiation of Cannabis Use: A 4-Year Longitudinal and Prospective Study. Biol Psychiatry 2011 Nov 28.
248. Whittle S. The neurobiological correlates of temperament in early adolescence. Melbourne, Australia: The University of Melbourne; 2006.
249. Whittle S, Allen NB, Lubman BI, Yücel M. The Neurobiological Basis of Temperament: Towards a Better Understanding of Psychopathology. Neurosci Biobehavioral Rev 2006; 30: 511-25.
250. Whittle S, Yap MB, Yücel M, et al. Prefrontal and amygdala volumes are related to adolescents' affective behaviors during parent-adolescent interactions. Proceedings of the National Academy of Sciences of the United States of America. [Research Support, Non-U.S. Gov't] 2008; 105(9): 3652-7.
251. Oshri A, Rogosch FA, Burnette ML, Cicchetti D. Developmental pathways to adolescent cannabis abuse and dependence: child maltreatment, emerging personality, and internalizing versus externalizing psychopathology. Psychology of addictive behaviors: J the Society of Psychologists in Addictive Behaviors. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't] 2011; 25(4): 634-44.
252. Hussey JM, Chang JJ, Kotch JB. Child maltreatment in the United States: prevalence, risk factors, and adolescent health consequences. Pediatrics. [Research Support, N.I.H., Extramural] 2006; 118(3): 933-42.
253. Zipursky AR, Whittle S, Yucel M, et al. Pituitary volume prospectively predicts internalizing symptoms in adolescence. J child psychology and psychiatry, and allied disciplines. [Research Support, Non-U.S. Gov't] 2011; 52(3): 315-23.